Skip to search formSkip to main contentSkip to account menu

agalsidase beta

Known as: agalsidase beta [Chemical/Ingredient] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Fabry disease, an X-linked inherited lysosomal storage disorder, is caused by mutations in the gene encoding α-galactosidase, GLA… 
Review
2017
Review
2017
Background:In 2009, the agalsidase beta shortage resulted in switching to agalsidase alfa treatment for many Fabry disease… 
Highly Cited
2012
Highly Cited
2012
Background. The purpose of this study was to identify determinants of renal disease progression in adults with Fabry disease… 
Review
2012
Review
2012
  • G. Keating
  • BioDrugs : clinical immunotherapeutics…
  • 2012
  • Corpus ID: 40445936
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase… 
Review
2012
Review
2012
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase… 
2011
2011
PurposeAnderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and is… 
Review
2010
Review
2010
Disclosure: The Fabry Registry is sponsored by Genzyme Corporation. U.F.-R., K.S., R.J.H., M.B., A.M., and A.P.B. serve on the… 
Review
2007
Review
2007
Context Fabry disease is an X-linked storage disorder characterized by deficient lysosomal enzyme activity and excessive… 
Highly Cited
2005
Review
2004
Review
2004
Summary: Fabry disease is a rare lysosomal storage disorder resulting from deficient activity of α-galactosidase A and subsequent…